GBA-PD, GD, and α-Synuclein Pipeline
Sources covering the GBA / Gaucher Disease (GD) / GBA-PD / α-synuclein arc. This is the largest section in the corpus and spans the GBA-PD biomarker matrix, GD/GBA-PD pipeline tables, compound entries (eliglustat, ambroxol, venglustat, isofagomine, TAK-341, TAK-071), the Prevail PR001 program, the α-synuclein supplement (animal models, antibodies, postmortem, propagation, fragments, biobanks/CEI), and downstream BIOMARKER cells.
Source-of-truth pages live in data/processed/markdown/by-photo/. Each row below points first to the KB source note (which carries the heading list) and then to the canonical transcription.
Sources in this section: 198
Top-level nav clusters: 17
Pipeline of GD & GBA-PD
179 source pages
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_181741 | Page 1 of 25 | Pipeline of GD & GBA-PD | note | md |
20240722_181748 | Page 1 of 25 | Pipeline of GD & GBA-PD > Summary | note | md |
20240722_181752 | Page 4 of 26 | Pipeline of GD & GBA-PD > Summary | note | md |
20240722_181756 | Page 4 of 26 | Pipeline of GD & GBA-PD > Venglustat (Ibiglustat) | note | md |
20240722_181800 | Page 4 of 26 | Pipeline of GD & GBA-PD > Prevail PR001 | note | md |
20240722_181805 | Page 4 of 26 | Pipeline of GD & GBA-PD > Prevail PR001 | note | md |
20240722_181809 | Page 20 of 28 | Pipeline of GD & GBA-PD > Prevail PR001 | note | md |
20240722_181813 | Page 20 of 28 | Pipeline of GD & GBA-PD > Summary | note | md |
20240722_181818 | Page 27 of 33 | Pipeline of GD & GBA-PD > TAK-341 (MEDI1341) > PK/PD model | note | md |
20240722_182123 | Page 144 of 150 | Pipeline of GD & GBA-PD > Summary | note | md |
20240722_182126 | Page 144 of 150 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity | note | md |
20240722_182130 | Page 144 of 150 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity | note | md |
20240722_182133 | Page 144 of 150 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity | note | md |
20240722_182136 | Page 144 of 150 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > Summary GBA protein & activity, GlcCer, GlcSph | note | md |
20240722_182139 | Page 144 of 150 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > Summary GBA protein & activity | note | md |
20240722_182143 | Page 144 of 150 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > Read the Paper | note | md |
20240722_182146 | Page 144 of 150 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity | note | md |
20240722_182149 | Page 144 of 150 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > a-syn POSTMORTEM | note | md |
20240722_182153 | Page 197 of 204 | Pipeline of GD & GBA-PD > Summary > GBA | note | md |
20240722_182157 | Page 200 of 208 | Pipeline of GD & GBA-PD > GBA > Structure of GBA protein | note | md |
20240722_182200 | Page 200 of 208 | Pipeline of GD & GBA-PD > GBA > GBA activity (BGL test) | note | md |
20240722_182203 | Page 200 of 208 | Pipeline of GD & GBA-PD > GBA > Catalytic pathway | note | md |
20240722_182207 | Page 200 of 208 | Pipeline of GD & GBA-PD > GBA > Catalytic pathway > Gangliosides | note | md |
20240722_182210 | Page 200 of 208 | Pipeline of GD & GBA-PD > GBA > Catalytic pathway > Gangliosides | note | md |
20240722_182213 | Page 200 of 208 | Pipeline of GD & GBA-PD > GBA > Catalytic pathway > Gangliosides > GlcSph | note | md |
20240722_182216 | Page 200 of 208 | Pipeline of GD & GBA-PD > GD > Mutations Summary | note | md |
20240722_182219 | Page 200 of 208 | Pipeline of GD & GBA-PD > GD > Types and Neuropathology | note | md |
20240722_182224 | Page 200 of 208 | Pipeline of GD & GBA-PD > GD > Parameters > GD 1 Summary | note | md |
20240722_182227 | Page 200 of 208 | Pipeline of GD & GBA-PD > GD > Parameters > GD 3 Summary | note | md |
20240722_182230 | Page 200 of 208 | Pipeline of GD & GBA-PD > GD > Parameters > GD 3 Summary | note | md |
20240722_182233 | Page 200 of 208 | Pipeline of GD & GBA-PD > GD > Animal models of GD | note | md |
20240722_182237 | Page 200 of 208 | Pipeline of GD & GBA-PD > GD > Animal models of GD | note | md |
20240722_182241 | Page 200 of 208 | Pipeline of GD & GBA-PD > GD > Animal models of GD > Outcome measure in nGD | note | md |
20240722_182245 | Page 200 of 208 | Pipeline of GD & GBA-PD > GD > Parameters > Oculomotor measurements | note | md |
20240722_182248 | Page 200 of 208 | Pipeline of GD & GBA-PD > GD > Parameters > Retina in nGD | note | md |
20240722_182252 | Page 200 of 208 | Pipeline of GD & GBA-PD > GD > Parameters > Oculomotor measurements | note | md |
20240722_182255 | Page 200 of 208 | Pipeline of GD & GBA-PD > GBA-PD > Mutation GBA-PD | note | md |
20240722_182259 | Page 200 of 208 | Pipeline of GD & GBA-PD > GBA-PD > MOA GBA-PD | note | md |
20240722_182303 | Page 200 of 208 | Pipeline of GD & GBA-PD > GBA-PD > Motor vs Cognition | note | md |
20240722_182306 | Page 200 of 208 | Pipeline of GD & GBA-PD > GBA-PD > Animal models of GBA-PD | note | md |
20240722_182310 | Page 261 of 267 | Pipeline of GD & GBA-PD > GBA-PD > Correction studies | note | md |
20240722_182313 | Page 261 of 267 | Pipeline of GD & GBA-PD > GBA-PD > Correction studies | note | md |
20240722_182316 | Page 261 of 267 | Pipeline of GD & GBA-PD > GBA-PD > GBA vs UPDRS vs MOCA | note | md |
20240722_182320 | Page 261 of 267 | Pipeline of GD & GBA-PD > GBA-PD > GBA vs UPDRS vs MOCA | note | md |
20240722_182323 | Page 261 of 267 | Pipeline of GD & GBA-PD > GBA-PD > GBA vs UPDRS vs MOCA | note | md |
20240722_182326 | Page 261 of 267 | Pipeline of GD & GBA-PD > GBA-PD > PET Imaging GBA | note | md |
20240722_182330 | Page 276 of 282 | Pipeline of GD & GBA-PD > GBA-PD > PET Imaging GBA | note | md |
20240722_182333 | Page 276 of 282 | Pipeline of GD & GBA-PD > GBA-PD > PET Imaging GBA > GBA Activator | note | md |
20240722_182336 | Page 276 of 282 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > RD-DDU GBA Activator | note | md |
20240722_182339 | Page 276 of 282 | Pipeline of GD & GBA-PD > GBA-PD > GBA GT > Executive summary | note | md |
20240722_182343 | Page 289 of 295 | Pipeline of GD & GBA-PD > GBA-PD > GBA GT > NHP studies > SNBR (Shin Nippon Biomedical Laboratories) | note | md |
20240722_182346 | Page 289 of 295 | Pipeline of GD & GBA-PD > GBA-PD > GBA GT > TM GT GBA-PD | note | md |
20240722_182351 | Page 295 of 301 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > NHP Translational Model | note | md |
20240722_182355 | Page 295 of 301 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Competitor | note | md |
20240722_182358 | Page 295 of 301 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Competitor > Fusion Protein | note | md |
20240722_182402 | Page 295 of 301 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > RD DDU’s PET Imaging GBA | note | md |
20240722_182406 | Page 307 of 312 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Acid ceramidase inhibitor | note | md |
20240722_182409 | Page 309 of 315 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > GALC (galactosylceramidase) > Genetics GALC for PD | note | md |
20240722_182412 | Page 309 of 315 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > GalactosylSph (=psychosine) > Assay of GalactosylSph | note | md |
20240722_182416 | Page 309 of 315 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Pipeline of KD > Target validation and correction | note | md |
20240722_182419 | Page 309 of 315 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Target validation and correction > 총정리중 GBA+PD에서 Lys | note | md |
20240722_182422 | Page 309 of 315 | Pipeline of GD & GBA-PD > Supplement > CNS & PNS > Cerebral Cortex | note | md |
20240722_182426 | Page 309 of 315 | Pipeline of GD & GBA-PD > Supplement > Cerebral Cortex > Neuron > Synapse | note | md |
20240722_182429 | Page 309 of 315 | Pipeline of GD & GBA-PD > Supplement > Neuron > Synapse > Postsynaptic density > Cranial nerve | note | md |
20240722_182433 | Page 309 of 315 | Pipeline of GD & GBA-PD > Supplement > Cranial nerve > Facial n > Nigrostriatal pathway > Basal Ganglia | note | md |
20240722_182436 | Page 309 of 315 | Pipeline of GD & GBA-PD > Supplement > Basal Ganglia > MBN (nucleus basalis of M…) > Development of brain (bra…) > Brainstem | note | md |
20240722_182440 | Page 333 of 340 | Pipeline of GD & GBA-PD > Supplement > Gut > Commissures > Anatomy-Neurological signs > General | note | md |
20240722_182443 | Page 337 of 342 | Pipeline of GD & GBA-PD > Supplement > PD > Animal model > CROs > Database > Antibody > Epitope mapping | note | md |
20240722_182447 | Page 340 of 345 | Pipeline of GD & GBA-PD > Supplement > Antibody > Epitope mapping > APOE > AQP4 potentiator | note | md |
20240722_182451 | Page 340 of 345 | Pipeline of GD & GBA-PD > Supplement > PET for astrocyte > aSyn > Animal models of aSyn > Non-Spreading Models | note | md |
20240722_182454 | Page 340 of 345 | Pipeline of GD & GBA-PD > Supplement > aSyn > Animal models of aSyn > Non-Spreading Models > Spreading Models | note | md |
20240722_182457 | Page 340 of 345 | Pipeline of GD & GBA-PD > Supplement > aSyn > Animal models of aSyn > Spreading Models | note | md |
20240722_182501 | Page 351 of 357 | Pipeline of GD & GBA-PD > Supplement > aSyn > Animal models of aSyn > Non-Spreading Models > Spreading Models | note | md |
20240722_182504 | Page 351 of 357 | Pipeline of GD & GBA-PD > Supplement > Non-Spreading Models > Spreading Models > Summary of a-syn animal models > MOA of aSyn s… | note | md |
20240722_182507 | Page 351 of 357 | Pipeline of GD & GBA-PD > Supplement > Summary of a-syn animal models > MOA of aSyn spreading > Antibodies to aSyn > Astrocytic… | note | md |
20240722_182510 | Page 359 of 365 | Pipeline of GD & GBA-PD > Supplement > MOA of aSyn spreading > Antibodies to aSyn > Astrocytic aSyn > CSF & Blood (a-syn) | note | md |
20240722_182514 | Page 359 of 365 | Pipeline of GD & GBA-PD > Supplement > Astrocytic aSyn > CSF & Blood (a-syn) > Distribution > Expression of aSyn | note | md |
20240722_182518 | Page 359 of 365 | Pipeline of GD & GBA-PD > Supplement > Function (of normal aSyn) > Grading/Scoring of LB pathology > Homology > In vitro studie… | note | md |
20240722_182522 | Page 359 of 365 | Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aS… > Oligodendrocytic aSyn > PET aSyn | note | md |
20240722_182524 | Page 359 of 365 | Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aSyn > Oligodendrocytic aSyn > PET aSyn | note | md |
20240722_182528 | Page 359 of 365 | Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aSyn > Oligodendrocytic aSyn > PET aSyn | note | md |
20240722_182532 | Page 359 of 365 | Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aSyn > Oligodendrocytic aSyn > PET aSyn | note | md |
20240722_182535 | Page 359 of 365 | Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aSyn > Oligodendrocytic aSyn > PET aSyn | note | md |
20240722_182539 | Page 359 of 365 | Pipeline of GD & GBA-PD > Supplement > Neurodegeneration and aSyn > Oligodendrocytic aSyn > PET aSyn > Postmortem aSyn | note | md |
20240722_182542 | Page 359 of 365 | Pipeline of GD & GBA-PD > Supplement > Postmortem aSyn > Release > Safety for aSyn > KO of α-syn > Seed-Amplification Assay | note | md |
20240722_182545 | Page 359 of 365 | Pipeline of GD & GBA-PD > Supplement > Safety for aSyn > KO of α-syn > Seed-Amplification Assay > Quantification | note | md |
20240722_182549 | Page 359 of 365 | Pipeline of GD & GBA-PD > Supplement > Seed-Amplification Assay > Quantification > Utility > Sources of aSyn | note | md |
20240722_182552 | Page 359 of 365 | Pipeline of GD & GBA-PD > Supplement > Sources of aSyn > Skin aSyn > Species > Native conformation > Summary aSyn species | note | md |
20240722_182556 | Page 394 of 399 | Pipeline of GD & GBA-PD > Supplement > Summary aSyn species > NDE > Fragments (Truncation) > Assay Truncation | note | md |
20240722_182559 | Page 394 of 399 | Pipeline of GD & GBA-PD > Supplement > Summary aSyn species > NDE > Fragments (Truncation) > Assay Truncation | note | md |
20240722_182602 | Page 394 of 399 | Pipeline of GD & GBA-PD > Supplement > NDE > Fragments (Truncation) > Assay Truncation > Structure of aSyn | note | md |
20240722_182606 | Page 394 of 399 | Pipeline of GD & GBA-PD > Supplement > Assay Truncation > Structure of aSyn > Synapse and aSyn > TM for aSyn programs | note | md |
20240722_182609 | Page 407 of 413 | Pipeline of GD & GBA-PD > Supplement > Synapse and aSyn > TM for aSyn programs > Turnover of aSyn > ATP13A2 (Park9) | note | md |
20240722_182613 | Page 407 of 413 | Pipeline of GD & GBA-PD > Supplement > ATP13A2 (Park9) > BBB / disruption / opener > BD > Process / BeyondBio > Biobank | note | md |
20240722_182617 | Page 407 of 413 | Pipeline of GD & GBA-PD > Supplement > Process > BeyondBio > Biobank > MJF | note | md |
20240722_182620 | Page 407 of 413 | Pipeline of GD & GBA-PD > Supplement > BeyondBio > Biobank > MJF > Netherlands Brain Bank | note | md |
20240722_182624 | Page 407 of 413 | Pipeline of GD & GBA-PD > Supplement > BeyondBio > Biobank > MJF > Netherlands Brain Bank | note | md |
20240722_182627 | Page 423 of 429 | Pipeline of GD & GBA-PD > Supplement > Biobank > MJF > Netherlands Brain Bank > Imperial College Brain Bank | note | md |
20240722_182630 | Page 423 of 429 | Pipeline of GD & GBA-PD > Supplement > MJF > Netherlands Brain Bank > Imperial College Brain Bank > Other Biobanks | note | md |
20240722_182634 | Page 423 of 429 | Pipeline of GD & GBA-PD > Supplement > MJF > Netherlands Brain Bank > Imperial College Brain Bank > Other Biobanks | note | md |
20240722_182637 | Page 423 of 429 | Pipeline of GD & GBA-PD > Supplement > Netherlands Brain Bank > Imperial College Brain Bank > Other Biobanks > Biobanks in Japan | note | md |
20240722_182641 | Page 423 of 429 | Pipeline of GD & GBA-PD > Supplement > Imperial College Brain Bank > Other Biobanks > Biobanks in Japan > BIOMARKER | note | md |
20240722_182644 | Page 423 of 429 | Pipeline of GD & GBA-PD > Supplement > Imperial College Brain Bank > Other Biobanks > Biobanks in Japan > BIOMARKER | note | md |
20240722_182704 | Page 440 of 447 | Pipeline of GD & GBA-PD > Supplement > Imperial College Brain Bank > Other Biobanks > Biobanks in Japan > BIOMARKER | note | md |
20240722_182708 | Page 440 of 447 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra | note | md |
20240722_182711 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Blood | note | md |
20240722_182715 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Blood | note | md |
20240722_182718 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Blood > PBMC > Vendors o… | note | md |
20240722_182722 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Braak Staging | note | md |
20240722_182725 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Braak Staging | note | md |
20240722_182728 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Companies CEI | note | md |
20240722_182732 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Companies CEI | note | md |
20240722_182735 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Companies CEI | note | md |
20240722_182738 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Companies CEI | note | md |
20240722_182742 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Summary CEI | note | md |
20240722_182745 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Summary CEI | note | md |
20240722_182749 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Summary CEI | note | md |
20240722_182752 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Cerevance > Delive… | note | md |
20240722_182755 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Cerevance > Team | note | md |
20240722_182758 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Circuits > Direct pathway | note | md |
20240722_182802 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Circuits > Indirect pathway | note | md |
20240722_182805 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dose finding > Dose sele… | note | md |
20240722_182808 | Page 446 of 453 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dose finding > Sample si… | note | md |
20240722_182811 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dose finding > Delayed s… | note | md |
20240722_182815 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Prevalence | note | md |
20240722_182818 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > vMRI | note | md |
20240722_182821 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Pathology | note | md |
20240722_182824 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Consortium | note | md |
20240722_182827 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Consortium | note | md |
20240722_182830 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Contacts | note | md |
20240722_182833 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > CSF | note | md |
20240722_182836 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > CSF Flow | note | md |
20240722_182839 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Human CSF … | note | md |
20240722_182842 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Interferon… | note | md |
20240722_182845 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Multiplex … | note | md |
20240722_182848 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Diagnosis … | note | md |
20240722_182851 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Digital Tr… | note | md |
20240722_182854 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Digital Tr… | note | md |
20240722_182857 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Digital Tr… | note | md |
20240722_182900 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Disease ar… | note | md |
20240722_182904 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > DLB vs PDD… | note | md |
20240722_182907 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > DLB vs PDD… | note | md |
20240722_182910 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > DNA damage | note | md |
20240722_182913 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Dopami… | note | md |
20240722_182916 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Summar… | note | md |
20240722_182919 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Dopa I… | note | md |
20240722_182922 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine transporter Ima… | note | md |
20240722_182926 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine transporter Ima… | note | md |
20240722_182929 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine transporter Ima… | note | md |
20240722_182932 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Neurom… | note | md |
20240722_182935 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Neurom… | note | md |
20240722_182938 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Neurom… | note | md |
20240722_182941 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability | note | md |
20240722_182944 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability > DWI vs DTI | note | md |
20240722_182947 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability > DWI vs DT… | note | md |
20240722_182950 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability > DWI vs DT… | note | md |
20240722_182953 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability > DWI vs DT… | note | md |
20240722_182956 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > EEG > Bands > EEG in PD … | note | md |
20240722_182959 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > EEG > EEG in PD > Limita… | note | md |
20240722_183002 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > EEG > Effect size > Effi… | note | md |
20240722_183006 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Electrophysiology > Anat… | note | md |
20240722_183009 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Electrophysiology > Proc… | note | md |
20240722_183012 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Endoplasmic Reticulum (E… | note | md |
20240722_183015 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Oligodendrocyte-derived … | note | md |
20240722_183018 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > GABA imaging > Gait > 4 … | note | md |
20240722_183021 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Gladstone Institute > Gl… | note | md |
20240722_183024 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Goals > FY22 > GWAS > Mo… | note | md |
20240722_183028 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > GWAS > Modifiers > Summa… | note | md |
20240722_183031 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > GWAS > Summary > LSD gen… | note | md |
20240722_183034 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > GPR37 > Glossary > H&Y (… | note | md |
20240722_183037 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > H&Y (Hoehn and Yahr) > H… | note | md |
20240722_183040 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Hearing loss > Heuron > … | note | md |
20240722_183044 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > HR Performance Review (i… | note | md |
20240722_183047 | Page 498 of 504 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Immunity > Autoimmunity … | note | md |
20240722_183050 | Page 626 of 632 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Inflammation > ALS > aSy… | note | md |
20240722_183055 | Page 626 of 632 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Comorbidity > Signals > … | note | md |
20240722_183058 | Page 626 of 632 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Inflammasome > In vitro … | note | md |
20240722_183101 | Page 626 of 632 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Inflammasome > In vitro … | note | md |
20240722_183115 | Page 626 of 632 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Inflammasome > In vitro … | note | md |
Brain Bank
2 source pages
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184200 | Page 925 of 935 | Brain Bank | note | md |
20240722_184203 | Page 925 of 937 | Brain Bank > Clinical Progression > Clinical Trial example > Cohort | note | md |
Pipeline of PD
2 source pages
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184327 | Page 1002 of 1008 | Pipeline of PD > aSyn - Antibody > aSyn - Small molecules | note | md |
20240722_184330 | Page 1008 of 1017 | Pipeline of PD > aSyn - Vaccine | note | md |
Studies of 31P MRS
2 source pages
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_183514 | Page 882 of 888 | Studies of 31P MRS > MELAS (Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) > MJFF | note | md |
20240722_183518 | Page 882 of 889 | Studies of 31P MRS > Oliver Bandmann, MD,… > MELAS (Mitochondrial enc…) > MJFF | note | md |
aSyn programs
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_181827 | Page 34 of 40 | aSyn programs > aSyn Propagation Suppressor | note | md |
Inflammation
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_183135 | Page 661 of 670 | Inflammation > NLRP3 > Neuronal > Caspase 1 > aSyn splicing > Catalytic cleft | note | md |
MSA
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184156 | Page 922 of 933 | MSA > aSyn in MSA > CSF aSyn in MSA | note | md |
PARKN GT (Takeshi Hioki, PFR-4249-100)
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_182103 | Page 144 of 150 | PARKN GT (Takeshi Hioki, PFR-4249-100) > RD DDU’s PET Imaging GBA > PK/PD Strategy | note | md |
PD and PGRN
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184413 | Page 1048 of 1056 | PD and PGRN > MJF > Prophylactic vs Therapeutic > Protein tags | note | md |
PDE
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184324 | Page 1002 of 1008 | PDE > PIAS2 > Pipeline of PD > aSyn - Antibody | note | md |
RBD PDD/DLB
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_184437 | Page 1072 of 1082 | RBD PDD/DLB > GBA pathway in RBD > NCNP collaboration for RBD > Reference range (normal range) | note | md |
ShareFolder
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_183436 | Page 829 of 835 | ShareFolder > Mitochondria > Astrocyte > asyn and mitochondria > Evidence in sPD | note | md |
SNCA ASO (WAVE)
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_181835 | Page 34 of 40 | SNCA ASO (WAVE) > Clinical plan of SNCA ASO | note | md |
SNCA BTV (HDO) (PFR-4067-100)
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_181831 | Page 34 of 40 | SNCA BTV (HDO) (PFR-4067-100) > Executive summary (Ryouta Maeda) | note | md |
TAK-071
1 source page
TAK-341 (MEDI1341)
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_181822 | Page 31 of 37 | TAK-341 (MEDI1341) > Clinical studies | note | md |
α-Synuclein and Lewy pathology in Parkinson’s disease
1 source page
| photo | page | nav path | source note | transcription |
|---|---|---|---|---|
20240722_182120 | Page 144 of 150 | α-Synuclein and Lewy pathology in Parkinson’s disease > Supplement Positive vs Negative | note | md |